Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...

Markets enter the week on edge as Q2 earnings season kicks off with heavyweight banks and global blue chips. Investors will ...

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade) SA analyst upgrades: NVDA, MAIN, ALB, APP, QBTS, HIMS (Update) Anavex Life Sciences GAAP EPS of -$0.13 beats by $0.02 ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

SO Britain’s second-least worst prince is on manoeuvres. Prince Andrew’s nephew, Harry, has been quietly negotiating behind ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

Bhubaneswar: In view of the self-immolation attempt by a 20-year-old student over alleged sexual harassment at a college in Balasore district on Satur.

We came across a bearish thesis on Hims & Hers on FJ Research’s Substack. As of 3ʳᵈ July, Hims & Hers’s share was trading at ...

President Donald Trump will announce $70 billion in artificial intelligence and energy investments in Pennsylvania on Tuesday, as part of White House efforts to accelerate development of emerging ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...